Austin, Texas and Auckland, New Zealand (PRWEB) September 10, 2013
Emergent Technologies, Inc. a leading innovation solutions company and KODE Biotech, Ltd, developer of the revolutionary KODE™ biosurface modification technology, have entered into a commercialization agreement in which Emergent will be KODE Biotech’s agent for technology commercialization. The agreement provides for revenue sharing between Emergent and KODE Biotech and has the potential to generate $5 – 10M in annual licensing revenues.
Biological processes are mediated by cell-cell and cell-surface interactions. KODE™ biosurface modification technology provides “biological paints” that can be used to apply virtually any bioactive compound to virtually any surface in just minutes without the need for any specialized equipment.
“Our technology represents a platform of constructs that can be used to modify cells, viruses, gels, solutions and solids such as glass and metal,” said Steve Henry, KODE Biotech’s CEO/CSO and Professor of Biotech Innovation at the Auckland University of Technology (AUT) Biotech Innovation Centre. “We have a proven track record in the transfusion medicine industry, where our products are being used to make quality controls and specialized diagnostic screening assays in a variety of novel diagnostic and therapeutic products."
“KODE Biotech’s technological capabilities and broad platform are a perfect fit for our innovation-based, partner-driven model,” said Thomas Harlan, Emergent CEO. “Our expertise is in locating, e
Copyright©2012 Vocus, Inc.
All rights reserved